Top 10 Medical VC Funds in Norway
A list of 10 VC funds that invest in Medical startups based in Norway. We rank investors based on the number of investments they made in Medical companies from Norway. We update this investor list every month.Top 10 Medical VC Funds in Norway
Investor | Medical Norway investments |
---|---|
Birk Venture | 4 |
SR One | 1 |
Investinor | 1 |
Advent Life Sciences | 1 |
Project Sandwater | 1 |
Yabeo Capital | 1 |
HealthCap | 1 |
Hadean Ventures | 1 |
Advent Venture Partners | 1 |
Canica | 1 |
Birk Venture is a Scandinavian venture company exclusively focusing on the life science industry.
Show more
Investment focus
- Biotechnology, Medical, Health Care
- Seed, Series A, Funding Round
- Norway, United Kingdom
Portfolio highlights
- APIM Therapeutics — APIM Therapeutics is based on an original discovery by Prof. Marit Otterlei and co-inventors at the Department of Cancer Research and Molecular Medicine at NTNU (Trondheim, Norway). The company is currently developing proprietary peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen), a key DNA repair protein regulating cellularresponses to DNA damage and stress.
- Zelluna Immunotherapy — Zelluna Immunotherapy AS is a privately owned biopharmaceutical company focused on the development of TCR based immunotherapies.
- Accession Therapeutics — Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells. As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour. Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- Avalyn Pharma — This does NOT display on the home page
- Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
- Odyssey Therapeutics — Odyssey Therapeutics is developing innovative medicines to make extraordinary leaps in outcomes for patients with cancer inflammatory diseases
Investinor invests in Norwegian based, high potential companies that are internationally oriented and in the phases ranging from early growth to expansion. The company has BNOK 4.2 ($500 m) under management and focus on companies within the internet, software, semiconductors, energy, cleantech, marine and life sciences sectors.
Show more
Investment focus
- Software, Manufacturing, Biotechnology
- Funding Round, Seed, Series A
- Norway, United States, Switzerland
Portfolio highlights
- Eyr — Eyr offers digital tools for medical consulting and doctor's prescription regarding various health issues.
- Nomono — The Next Generation Audio company.
- Calluna Pharma — Join Calluna Pharma on our mission to revolutionize the treatment of inflammatory and fibrotic diseases. With a robust pipeline, seasoned leadership, and strategic alliances, help us reshape the treatment landscape for the better.
Advent Life Sciences is a venture team investing in life sciences businesses. The team consists of 11 professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The Firm invests in a range of sectors within life sciences,principally in new drug discovery, enabling technologies, and med tech. Realizations in the last three years include Algeta, Avila, CN Creative, EUSA, Micromet. Current investments include Acutus, Biocartis, Cellnovo, f2G, NeRRe,
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Funding Round, Series B
- United States, United Kingdom, France
Portfolio highlights
- Argá Medtech — Developing the next generation of Pulsed Field Ablation and Irreversible Electroporation Venture-capital backed company
- PIC Therapeutics — PIC Therapeutics is a biotechnology company focused on fundamentally changing how we treat cancer by developing a new generation of therapeutics based on the modulation of RNA translation.
- Curve Therapeutics — Curve has developed an innovative screening platform that is transforming the discovery of first-in-class therapeutics. The platform allows functional screening of diverse, genetically encoded Microcycle™ libraries against a broad range of disease-associated targets that are present in their native conformation inside a mammalian cell. Curve isdeploying this platform to build a pipeline of novel cancer drugs.
Project Sandwater is a fresh take on venture investments within the Nordics and beyond.
Show more
Investment focus
- Medical, Consulting, Life Science
- Series A
- Norway, The Netherlands
Portfolio highlights
- Delft IMP — Delft IMP (Intensified Materials Production) commercializes nanostructuring of particles using atomic and molecular layer deposition (ALD and MLD), based on the patented and publicized IP and know-how developed within the Product & Process Engineering (PPE) group at Delft University of Technology. Following various feasibility projects betweenindustry and university, Delft IMP was initiated end 2014 to truly commercialize the technology.
- Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.
We are an early-stage investor that believes in flexible Evergreen funding without the limitations of traditional funds.
Show more
Investment focus
- Financial Services, Health Care, FinTech
- Series A, Seed, Funding Round
- Germany, United States, United Kingdom
Portfolio highlights
- Wellth — Improve quality scores, reduce high cost utilization, address health equity, and improve member satisfaction by using the right incentive at the right time to create life-changing healthy habits through Wellth.
- PIONIX — open source software as a service for charging stations / e-mobility
- Rabot Charge — Rabot Charge offers intelligent charging management solutions for customers to charge their electric cars at home.
HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Funding Round
- United States, Sweden, France
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Vicore Pharma — Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.
- Rampart Bioscience — Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases. It also offers proprietary development and delivery platforms, which together, create optimized therapeutics in a revocable, non-viral format. It also assists patients with genetically driven diseases by integrating capabilities from avariety of key scientific disciplines including gene delivery, protein sciences, and clinical translation.
Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region.
The funds are backed by leading private and institutional investors.
Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across theregion
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series A, Funding Round, Series B
- Sweden, Norway, Austria
Portfolio highlights
- Ribbon Biolabs — Ribbon Biolabs revolutionary technology for the fast and efficient automated synthesis of DNA is here to enable the new wave of biotechnological innovation.
- Alex Therapeutics — The Alex DTx Platform enables partners within pharma and health care to effectively and reliably launch new DTx treatments by leveraging existing insights, modules, processes and data.
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Advent Venture Partners is one of Europe's most successful growth and venture capital investors in market-leading tech and life sciences businesses. They have designed their strategy, teams and funds so they can focus on backing a select few companies. They pride their selves on establishing true partnerships with entrepreneurs in order tobuild valuable businesses together.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Series B, Series A, Funding Round
- United Kingdom, United States, Switzerland
Portfolio highlights
- Wiz — Organizations of all sizes and industries use Wiz to rapidly identify and remove the most critical risks in AWS, Azure, GCP, and Kubernetes so they can build faster and more securely.
- WorldStores — Established in 2008, Worldstores is now the UK’s largest online home & garden retailer. Offering unparalleled choice, value for money, customer service and a range of convenient delivery options, Worldstores is renowned as one of the UK's most exciting e-commerce success stories.ACHICA, the luxury flash-sale business, and baby specialistKiddicare also form part of the Worldstores Group and play a key part in the ambitious plans for Worldstores Group in becoming a household name in the home and garden market.
- Acutus Medical — Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists.Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Itsproducts are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals.It was founded in 2011 and headquartered in Carlsbad, California.
Canica is one of the largest privately owned investment companies in Norway. Our operations are focused on active, long-term ownership, primarily within sectors covering retail, fast moving consumer goods and real estate. Canica can offer core expertise within the fields of business development and finance, as well as capital and network in orderto create value and employment in a long-term perspective.
Show more
Investment focus
- Beauty, Medical, Biotechnology
- Private Equity, Series A, Series D
- Norway, Denmark, Switzerland
Portfolio highlights
- Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.
- Porterbuddy — They are the gang that delivers to your door the same day you order in the online store.Porterbuddy' is a logistics platform that provides efficient and customer-centric, last-mile delivery of products.
- Galecto — Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medicalneed. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Investors by industry
Health Care
Biotech
Community
Marketplace
FinTech
Impact
Proptech
Media (entertainment)
EdTech
Consumer
Climate
Energy
Hardware
Gaming
Artificial intelligence
Sustainability
Agriculture (agtech)
Venture Capital
Restaurants
Publishing
Beauty
Oil and Gas
Web3
Video Games
Food and Beverage
Clean Energy
Real Estate
Infrastructure
Big Data
Organic Food
Photography
Fashion
Education
B2B
Renewable Energy
Payments
Financial Services
Sporting Goods
Finance
Retail
Medical
Email
Wellness
Social Media
Music
Franchise
Celebrity
Android
Internet
Legal
Google
eSports
Construction
Local
Mobile
Recruiting
Platforms
Enterprise Software
Travel
Fitness
Mobile Advertising
Sports
Social Network
Cannabis
Biotechnology
Hospitality
Manufacturing
Digital Media
Automotive
Crowdfunding
Wine And Spirits
Facebook
Medical Device
Social
Art
CleanTech
Social Impact
Transportation
Mobile Apps
InsurTech
LGBT
Enterprise
Non Profit
Film
Life Science
Theatre
SaaS
Cryptocurrency
Software
Blockchain
Investors by country
Canada
United Kingdom
Ireland
Germany
South Korea
Australia
United States
India
New Zealand
Oceania
Armenia
China
Europe
Indonesia
LATAM
Middle East
Spain
Asia
Japan
South Africa
Qatar
Vietnam
Saudi Arabia
Singapore
Sri Lanka
Brazil
Africa
Czech Republic
Bahrain
Belize
Bermuda
Costa Rica
Belarus
Bulgaria
Denmark
Algeria
Georgia
Gibraltar
Cameroon
Chile
Finland
Estonia
Faroe Islands
Greece
Ethiopia
Ghana
Hungary
Croatia
Egypt
Belgium
Barbados
Ecuador
France
Hong Kong
Kuwait
Israel
Jersey
Kazakhstan
Nicaragua
Philippines
Italy
Mali
Lithuania
Seychelles
Slovenia
Russian Federation
Cambodia
Rwanda
Liechtenstein
Serbia
Uzbekistan
Togo
Taiwan
Kenya
Ukraine
Sierra Leone
Turkey
Tunisia
Thailand
Tajikistan
Poland
Uganda
Zimbabwe
Tanzania
San Marino
Uruguay
Venezuela
Liberia
Zambia
Senegal
Lebanon
Puerto Rico
Portugal
Sweden
Mauritius
El Salvador
Morocco
Malaysia
Nigeria
Norway
Bahamas
Azerbaijan
Iraq
Iceland
Namibia
Peru
United Arab Emirates
Honduras
Myanmar
Cayman Islands
Isle of Man
Bolivia
Panama
Luxembourg
Malta
Mexico
Pakistan
Albania
Argentina
Austria
Bangladesh
Grenada
Jordan
Romania
Cyprus
Latvia
Oman
Colombia
Switzerland
Guatemala
Marshall Islands
VC Funds in Norway by industry
Clean Energy
Oil and Gas
Transportation
Financial Services
Big Data
Payments
Food and Beverage
Medical
Medical Device
Internet
Social Media
Manufacturing
Music
Mobile
Blockchain
Construction
Software
Enterprise Software
Sports
CleanTech
EdTech
FinTech
Enterprise
Consumer
Climate
Sustainability
Energy
Proptech
Impact
SaaS
Marketplace
Hardware
Artificial intelligence
Community
Agriculture (agtech)
Gaming
Social
Web3
B2B
Education
Life Science
Biotechnology
Health Care
Real Estate
Biotech
Cryptocurrency
Publishing
Renewable Energy
Video Games
Media (entertainment)